

# Germany

## Tuberculosis profile

Population 2016

82 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.32 (0.32–0.33)	0.39 (0.39–0.4)
Mortality (HIV+TB only)	0.054 (0.026–0.091)	0.07 (0.03–0.11)
Incidence (includes HIV+TB)	6.6 (5.6–7.6)	8.1 (6.9–9.3)
Incidence (HIV+TB only)	0.35 (0.2–0.54)	0.43 (0.24–0.66)
Incidence (MDR/RR-TB)**	0.22 (0.11–0.34)	0.27 (0.13–0.41)

Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.24 (0.21–0.28)	1.9 (1.6–2.2)	2.2 (1.8–2.5)
Males	0.27 (0.23–0.31)	4.2 (3.5–4.8)	4.4 (3.8–5.1)
Total	0.51 (0.44–0.59)	6.1 (5.2–7)	6.6 (5.6–7.6)

TB case notifications, 2016

Total cases notified	5 915
Total new and relapse	5 737
- % tested with rapid diagnostics at time of diagnosis	55%
- % with known HIV status	
- % pulmonary	75%
- % bacteriologically confirmed among pulmonary	81%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.06 (0.05–0.07)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			160 (85–240)
Estimated % of TB cases with MDR/RR-TB	2.2% (0.82–4.8)	23% (16–30)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	65%	5 543
Previously treated cases, excluding relapse, registered in 2015	55%	173
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014	35%	93
XDR-TB cases started on second-line treatment in 2014	18%	11

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2017

National TB budget (US\$ millions)
------------------------------------


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB